At a Glance
Regime: All Time Highs, Indicators Hooking Up· Open: Flat · Risk on new positions: Improving · Custom T2108: 19 (Hooking Up),
Focus: ALEC (PR Catalyst · Magnitude) · PBR (PR Catalyst · Duration)
Secondary: ALAB · SDGR · XRPN
Tonight After Hours: AEHR · Tomorrow Before Open: —
Holding: OKTA, DELL, MRNA
Situational Awareness
Market Condition: All Time Highs/Setups Proliferating/Breadth Hooking Up
Commentary:
Flat open. Normal Monday morning. The biggest macro group move is in Brazil on the Presidential election looking Bolsonaro will be elected instead of Lula. Other than that in terms of the market there aren’t really any big carry over narratives from the weekend.
Last week closed strong and we are looking for follow through here. In my weekend work I saw a lot of setups proliferating as we come into Earnings Season. I think there are going to be some excellent opportunities. Patience is required to be fresh to hit the strongest catalysts when they occur. We don’t need to chase.
Two main stocks in focus today. A Brazil play in PBR and also a Biotech Licensing Agreement in ALEC.

10 Year Yield - We need this to come down for stocks to advance
On a technical note you will see some updates in the format of my newsletters on the weekend edition and also the daily to closer reflect my current daily process. Nothing major but the ‘‘Also in Play’’ section will try to show my watchlist for alternate setups that I trade - Parabolic Short, Shoryuken (Delayed Entry Setup), Power Play (Continuation Setups). These are the names that I refer to them. I operate these on a watchlist basis. I do not scan intraday or take trades on the fly. All the work is done outside of hours.
Today In Focus
ALEC — Alector: Alector Enters Global License Agreement with Roche
PR Catalyst · Magnitude · Mkt cap $201.0M · Float 77M · SI 7.9% (3.3 days) · Nasdaq · Theme: Small Caps
Why: Quite a large licensing agreement with Blue-chip company (Roche). $100m Up front and up to $1.17b in Milestone payments. Even the upfront amount is very large compared to ALEC current revs and also their market cap. Two year base. $3 round number pre market. There is already an ATM Offering registered since May. We don't know yet if they have already diluted or whether they will begin today. Interestingly Roche already have their own Parkinson’s programme so this is definitely a vote of confidence.
Level: $2.75 is the support undercut and $3 is your above and below level here. Above $3 is good and below is an avoid in my opinion.

PBR — Petróleo Brasileiro S.A. - Petrobras: Bolsonaro Presidential Election Win
PR Catalyst · Duration · Mkt cap $139B · Float 4.0B · SI 0.8% (1.3 days) · NYSE · Theme: Oil & Gas Integrated
Why: I was trying to find a good vehicle to express the Brazilian election news. For me PBR has the best chart. Nice consolidation on daily. A lot of names in Brazil are moving notably bank stocks and energy stocks. My view is that Oil is for sure in play in the macro environment. I assume that Bolsonaro, if elected will exploit the energy sector. This is not a massive conviction idea but it looks to me as the best play out of Brazil.
Level: $24 Pre Market High

Also in Play
Stocks in Play Watchlist: TradingView
Powerplay Watch: SDGR, ALAB, NET,



Parabolic Short Watch : XRPN

Trade Updates
Open:
MRNA - Power Play - 17th September 2026 - 40% Remaining
DELL - Earnings Catalyst - 2nd September 2026 - 70% Remaining
OKTA - Earnings Catalyst - 27th August 2026 - 10% Remaining
Trims:
MRNA - 4EMA Close Below - 30th September 2026 - 30% Trim
Closed this week:
TEAM - Earnings Catalyst - 28th September 2026 - 20EMA Close Below
Macro Events (Eastern Time)
Monday October 5 2026
10:00 AM - ISM Services PMI (Sep) (Previous: 55.4, Consensus: 55.7)
IPOs Today
Mon 5 Oct: TBCV - Thunder Bridge Capital Partners V, Ltd. Class A Ordinary Shares - NASDAQ - SPAC
Biotech Calendar
XBI -0.4% on the week and -6.6% on the month, under its 50-day. The sector tailwind is gone for now. Reactions have to prove themselves.
Flagged Charts: MRK, IRD, AGIO, INO, ZYME, IVVD, SYRE, DFTX
Note: Never front-run biotech catalysts. Wait for the catalyst to hit, then assess if the reaction is tradable. Dates are estimates and can shift.
Full H2 Biotech Watchlist: TradingView
Have a Great Week!
Sean Sharpe


